Bulletin
Investor Alert

New York Markets Open in:

Incyte Corp.

NAS: INCY

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 24, 2020, 4:07 p.m.

/zigman2/quotes/204510994/composite

$

85.07

Change

0.00 0.00%

Volume

Volume 24,025

Quotes are delayed by 20 min

/zigman2/quotes/204510994/composite

Previous close

$ 85.97

$ 85.07

Change

-0.90 -1.05%

Day low

Day high

$82.98

$85.31

Open

52 week low

52 week high

$62.48

$110.37

Open

Company Description

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib)...

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Valuation

P/E Current

41.87

P/E Ratio (without extraordinary items)

42.53

Price to Sales Ratio

8.80

Price to Book Ratio

7.26

Price to Cash Flow Ratio

26.74

Enterprise Value to EBITDA

35.57

Enterprise Value to Sales

7.86

Total Debt to Enterprise Value

0.00

Efficiency

Revenue/Employee

1,482,664.00

Income Per Employee

306,941.00

Receivables Turnover

7.00

Total Asset Turnover

0.71

Liquidity

Current Ratio

4.83

Quick Ratio

4.81

Cash Ratio

4.13

Profitability

Gross Margin

93.18

Operating Margin

19.53

Pretax Margin

22.55

Net Margin

20.70

Return on Assets

14.72

Return on Equity

19.76

Return on Total Capital

18.28

Return on Invested Capital

19.49

Capital Structure

Total Debt to Total Equity

2.77

Total Debt to Total Capital

2.70

Total Debt to Total Assets

2.10

Long-Term Debt to Equity

1.68

Long-Term Debt to Total Capital

1.64

Officers and Executives

Name Age Officer Since Title
Mr. Hervé Hoppenot 59 2014 President, Chief Executive Officer & Director
Ms. Christiana Stamoulis 48 2019 Chief Financial Officer & Executive Vice President
Dr. Steven H. Stein 52 2015 Chief Medical Officer & Senior Vice President
Dr. Dashyant Dhanak 58 2018 Chief Scientific Officer & Executive VP
Dr. Wenqing Yao 56 2002 Senior Vice President-Discovery Chemistry

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/11/2020 Maria E. Pasquale
EVP & General Counsel
127   Derivative/Non-derivative trans. at $65.36 per share. 8,300
09/10/2020 Maria E. Pasquale
EVP & General Counsel
2,193   Disposition at $90.83 per share. 199,190
09/10/2020 Maria E. Pasquale
EVP & General Counsel
2,193   Derivative/Non-derivative trans. at $65.36 per share. 143,334
09/08/2020 Dashyant Dhanak
EVP & Chief Scientific Officer
961   Disposition at $88.94 per share. 85,471
09/08/2020 Dashyant Dhanak
EVP & Chief Scientific Officer
961   Derivative/Non-derivative trans. at $65.42 per share. 62,868
08/27/2020 Wendy L. Dixon
Director
20,000   Disposition at $94.51 per share. 1,890,200
08/27/2020 Wendy L. Dixon
Director
20,000   Derivative/Non-derivative trans. at $18.97 per share. 379,400
08/10/2020 Maria E. Pasquale
EVP & General Counsel
128   Derivative/Non-derivative trans. at $65.36 per share. 8,366
08/06/2020 Dashyant Dhanak
EVP & Chief Scientific Officer
961   Disposition at $97.8 per share. 93,985
08/06/2020 Dashyant Dhanak
EVP & Chief Scientific Officer
961   Derivative/Non-derivative trans. at $65.42 per share. 62,868
07/16/2020 Steven H. Stein
EVP & Chief Medical Officer
766   Disposition at $103.83 per share. 79,533
07/15/2020 Hervé Hoppenot
Chairman / CEO; Director
2,420   Derivative/Non-derivative trans. at $104.25 per share. 252,285
07/15/2020 Steven H. Stein
EVP & Chief Medical Officer
623   Derivative/Non-derivative trans. at $104.25 per share. 64,947
07/15/2020 Paula J. Swain
EVP, Human Resources
626   Derivative/Non-derivative trans. at $104.25 per share. 65,260
07/15/2020 Barry P. Flannelly
EVP & General Manager US
639   Derivative/Non-derivative trans. at $104.25 per share. 66,615
07/15/2020 Paul Trower
Principal Accounting Officer
203   Derivative/Non-derivative trans. at $104.25 per share. 21,162
07/15/2020 Wenqing Yao
EVP, Head of Discovery Chem
639   Derivative/Non-derivative trans. at $104.25 per share. 66,615
07/13/2020 Dashyant Dhanak
EVP & Chief Scientific Officer
2,419   Derivative/Non-derivative trans. at $65.42 per share. 158,250
07/10/2020 Maria E. Pasquale
EVP & General Counsel
127   Derivative/Non-derivative trans. at $65.36 per share. 8,300
/news/latest/company/us/incy

MarketWatch News on INCY

  1. Incyte stock price target raised to $95 from $79 at Mizuho

    8:23 a.m. Aug. 5, 2020

    - Tomi Kilgore

  2. Lilly Is Testing Its Arthritis Drug as a Coronavirus Treatment

    8:41 a.m. June 15, 2020

    - Barron's Online

  3. Eli Lilly enrolls first patient in phase 3 trial of Olumiant for hospitalized patients with COVID-19

    6:49 a.m. June 15, 2020

    - Tomi Kilgore

  4. Eli Lilly's Olumiant is approved in 70 countries to treat rheumatoid arthritis

    6:50 a.m. June 15, 2020

    - Tomi Kilgore

  5. Loading more headlines...
/news/nonmarketwatch/company/us/incy

Other News on INCY

  1. Buy the dip in biotechs - RBC

    3:34 p.m. Sept. 21, 2020

    - Seeking Alpha

  2. Lilly's Olumiant Gets CHMP Nod for Eczema Label Expansion

    11:21 a.m. Sept. 21, 2020

    - Zacks.com

  3. Sector Watch: More oncology events as cancer ETF breaks out

    9:59 a.m. Sept. 20, 2020

    - Seeking Alpha

  4. Incyte FDA Approvals To Propel Future Growth

    1:28 p.m. Sept. 18, 2020

    - Seeking Alpha

  5. Lilly's Olumiant Meets Primary Endpoint in Coronavirus Study

    11:15 a.m. Sept. 15, 2020

    - Zacks.com

  6. Stock Market News for Sep 15, 2020

    9:44 a.m. Sept. 15, 2020

    - Zacks.com

  7. New U.S. Coronavirus Infections Fall From a Day Earlier

    6:23 p.m. Sept. 14, 2020

    - Ted Mann

  8. Lilly’s Arthritis Drug Helped Covid-19 Patients Recover Faster

    11:12 a.m. Sept. 14, 2020

    - Peter Loftus

  9. M&A Activities Intensify in Pharma Industry

    10:56 a.m. Sept. 14, 2020

    - Zacks.com

  10. No Econ Data, but Big Biopharma News

    10:19 a.m. Sept. 14, 2020

    - Zacks.com

  11. Calithera nixes 2017 collaboration deal with Incyte

    8:40 a.m. Sept. 4, 2020

    - Seeking Alpha

  12. Loading more headlines...

At a Glance

Incyte Corp.

1801 Augustine Cut-Off

Wilmington, Delaware 19803

Phone

1 3024986700

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$2.16B

Net Income

$446.91M

2019 Sales Growth

14.7%

Employees

1,456

/news/pressrelease/company/us/incy

Press Releases on INCY

  1. Nasdaq 100 Movers: INCY, LRCX

    10:21 a.m. Sept. 24, 2020

    - MarketNewsVideo.com

  2. Bullish Stocks With High ROI- $NTRS $TEL $INCY

    9:55 a.m. Sept. 11, 2020

    - The Market Signal

  3. Loading more headlines...
Link to MarketWatch's Slice.